Security National Bank of Sioux City Iowa IA reduced its position in AbbVie Inc. (NYSE:ABBV) by 0.8% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 14,164 shares of the company’s stock after selling 118 shares during the period. Security National Bank of Sioux City Iowa IA’s holdings in AbbVie were worth $1,532,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Alpha DNA Investment Management LLC acquired a new stake in shares of AbbVie during the fourth quarter worth $33,000. Core Wealth Advisors Inc. bought a new stake in AbbVie during the fourth quarter worth about $43,000. Wealthcare Capital Management LLC bought a new stake in AbbVie during the first quarter worth about $45,000. IronBridge Private Wealth LLC bought a new stake in AbbVie during the fourth quarter worth about $52,000. Finally, Prestige Wealth Management Group LLC raised its holdings in AbbVie by 50.1% during the fourth quarter. Prestige Wealth Management Group LLC now owns 542 shares of the company’s stock worth $58,000 after acquiring an additional 181 shares in the last quarter. 66.07% of the stock is owned by institutional investors.
A number of equities analysts have weighed in on the company. Piper Sandler boosted their price target on AbbVie from $120.00 to $124.00 and gave the stock an “overweight” rating in a research report on Friday, April 30th. Mizuho boosted their price target on AbbVie from $126.00 to $128.00 and gave the company a “buy” rating in a research note on Monday, May 3rd. SVB Leerink boosted their price target on AbbVie from $140.00 to $144.00 and gave the company an “outperform” rating in a research note on Tuesday, March 30th. BMO Capital Markets upped their target price on AbbVie from $127.00 to $129.00 and gave the stock an “outperform” rating in a research note on Monday, May 3rd. Finally, Royal Bank of Canada started coverage on AbbVie in a research note on Wednesday, April 7th. They issued a $135.00 price target for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company. AbbVie currently has an average rating of “Buy” and a consensus target price of $119.07.
AbbVie (NYSE:ABBV) last posted its earnings results on Thursday, April 29th. The company reported $2.95 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.83 by $0.12. AbbVie had a net margin of 10.28% and a return on equity of 136.75%. The firm had revenue of $13.01 billion for the quarter, compared to analysts’ expectations of $12.84 billion. During the same quarter last year, the firm earned $2.42 EPS. The company’s quarterly revenue was up 50.9% compared to the same quarter last year. On average, research analysts predict that AbbVie Inc. will post 12.6 EPS for the current fiscal year.
In other news, SVP Carrie C. Strom sold 4,184 shares of the firm’s stock in a transaction that occurred on Monday, May 3rd. The shares were sold at an average price of $112.40, for a total transaction of $470,281.60. Following the completion of the sale, the senior vice president now owns 63,409 shares in the company, valued at approximately $7,127,171.60. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.09% of the company’s stock.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Featured Article: Liquidity
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.